Aspira Women's Health Inc. (AWH) News
Filter AWH News Items
AWH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AWH News Highlights
- For AWH, its 30 day story count is now at 5.
- Over the past 13 days, the trend for AWH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ACXP, DEC and RELI are the most mentioned tickers in articles about AWH.
Latest AWH News From Around the Web
Below are the latest news stories about ASPIRA WOMEN'S HEALTH INC that investors may wish to consider to help them evaluate AWH as an investment opportunity.
Aspira Women’s Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024AUSTIN, Texas, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it will host a virtual R&D day featuring experts who will present the exciting progress of the company’s product pipeline on January 4, 2024 at 11:00 AM ET. To register, click here. Upcoming R&D Day: Aspira R&D Day: Updates on the Development of |
Aspira Women’s Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024Aspira management will be available for meetings in San Francisco (January 8-10, 2024) AUSTIN, Texas, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will be available for partnering and institutional one-on-one meetings in San Francisco, during JP Morgan’s Healthcare Conference Week 2024. Nicole |
New to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10:30 PM PTNew to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10;30 PM PT Episode 537: 1). Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) 2). Aspira Women's Health (NASDAQ: AWH) ($AWH) 3). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 4).The Business of Blockchain, 5).Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.newtothestreet.com/ NEW YORK, Dec. 08, 202 |
New to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PTNew to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PT Episode 536: 1). - Reliance Global Group, Inc. (NASDAQ: RELI) (NASDAQ: RELIW) ($RELI) 2). Aspira Women's Health (NASDAQ: AWH) ($AWH) 3). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 4). The Business of Blockchain 5).Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) (Sekur®) - https://www.ne |
Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for EndometriosisData supports EndoCheck™ to be the first blood test for the identification of localized endometriosis, including endometrioma Platform migration to begin on the Company’s EndoMDx™ test for broader endometriosis indications AUSTIN, Texas, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has completed the de |
Aspira Women’s Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per testAUSTIN, Texas, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that California Medicaid (Medi-Cal) added Ova1Plus® to its fee schedule. Aspira will be reimbursed at a rate of $897 for all Ova1Plus® tests proc |
Aspira Women’s Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)CMS approves OvaWatchSM 2024 price at $897 per test AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) rate setting process, the Centers for Medicare & Medicaid Services (CMS) has approved the crosswalk of the fee to be |
Aspira Women’s Health Reports Third Quarter 2023 Financial ResultsProduct revenue increased 9% to $2.2 million for the quarter, and 19% to $7.0 million year to date OvaSuite sales volume increased 5% to 5,783 units for the quarter, and 16% to 18,331 units year to date Third quarter cash utilization of $3.3 million, a decrease of 56% compared to third quarter last year Conference call and webcast scheduled for today 4:30 pm Eastern Time AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based w |
Aspira Women’s Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatchThe proposed rule would allow for OvaWatchSM to be reimbursed at the same rate as Ova1® at $897 per test and will become final following a brief public comment period AUSTIN, Texas, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) ra |
Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Monday, November 13, 2023AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30 p.m. Ea |